Cochlear shares (ASX: COH) are on a four day green streak that has added 9.91% to A$141.47, as investors continued to rotate back into large-cap healthcare ahead of the company’s annual general meeting next week. It has been a volatile year for holders, with the COH share price having fallen 65% through the first four months of the year, only to have bounced 57% from there. Such is maths, that this continues to leave the stock 45.8% lower since the turn of 2026.
The four day bounce appears to reflect positioning repair and renewed appetite for quality defensive names. The ASX’s recent gains have been powered partly by a healthcare comeback, with CSL, Cochlear and Pro Medicus all rebounding as in-line results collided with rock-bottom expectations.
Healthcare investors have also been signalling they want earnings clarity from this AGM season, and Cochlear’s meeting is one of the most watched. Shareholders will be looking for confirmation of calendar-year guidance, an update on US demand, and colour on how currency moves are feeding through to earnings. The AGM agenda includes remuneration and long-term incentive resolutions, which will keep governance in the frame as well.
The Setup
Looking to analysts for clues about what comes next, Ord Minnett updated its healthcare coverage on 19 October to reflect new currency forecasts, flagging only modest EPS downgrades of 0-3% for Cochlear across the forecast horizon while leaving recommendations unchanged. With downside revisions now quantified and relatively small, some of the uncertainty that hung over the stock through its early-October slide has been removed, giving buyers more confidence to step back in.The average price target sits at A$136.15, a few % below where the stock currently trades, with the rebound off lows overshooting the Street view.
The technical setup is consistent with a maturing rebound, as trend strength remains present, with the 14-day ADX near 30, though its falling profile suggests the uptrend off the October lows is established and potentially entering a later phase.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
A glance at the chart will show the stock trading above both the 30 day and 50 day SMAs, with near term momentum; yet below the 200 day at A$150.89 that would be the true test of momentum shifting. A$145 is the near term line in the sand for price resistance on the chart, although major moves may well wait until the AGM next week. Bulls will be eager for the direction of the next leg to be higher, with plenty of ground to make up from where the stock began 2026.
